Saturday, 22 June 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 22 June 2024
Listen to this story 
News

Drug wins ASCO standing ovation

Posted 5 June 2024 AM

AstraZeneca received a standing ovation at the American Society of Clinical Oncology (ASCO) 2024 annual meeting after presenting astonishing trial results for its EGFR inhibitor Tagrisso.

There is a reduction of 84 per cent in the risk of disease progression or death when using Tagrisso to treat patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumours have exon 19 deletions or exon 21 (L858R) mutations, after chemoradiotherapy (CRT) compared to a placebo, according to results from the LAURA Phase 3 trial.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (29)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (7)

Other (20)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.